The effect of dantrolene sodium on spasticity in multiple sclerosis.
D000328:Adult; D000368:Aged; D003620:Dantrolene / Q000009:adverse effects / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D009119:Muscle Contraction / Q000187:drug effects; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D009325:Nausea / Q000139:chemically induced; D010919:Placebos
D006827:Hydantoins; D009125:Muscle Relaxants, Central; D010919:Placebos; D003620:Dantrolene